Broken String Biosciences and the Francis Crick Institute advance ALS research
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis
12 May 2024
Broken String Biosciences, a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, has announced it has entered a research collaboration with the Francis Crick Institute, a world-leading biomedical discovery institute dedicated to understanding the biology underlying health and disease.
The project aims to develop novel applications for Broken String’s proprietary DNA break-mapping platform, INDUCE-seq™, beyond its established capabilities in gene-editing. The research will be focused on leveraging the technology to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS).
The majority of ALS cases (~90%) are considered sporadic1. Whilst there has been progress to better understand the genes and biological markers associated with the disease, very little is understood about the causes, with current treatment strategies focused on symptom management and slowing disease progression. Combining world-leading research from the Crick with Broken String’s expertise in genomics, sequencing, and bioinformatics, the partnership provides a unique opportunity to expand application of the Company’s INDUCE-seq technology in a key area of clinical unmet need, to support improved diagnosis and treatment of ALS.
The partnership has been secured via the Francis Crick Institute’s Business Engagement Fund, a new initiative supported by The Medical Research Council (MRC-UKRI), that is designed to encourage collaborations with small-to-medium sized enterprises (SMEs) and strengthen the Crick’s engagement with industry.
Dr. Simon Boulton, Principal Group Leader, the Boulton Lab (DSB Repair Metabolism) at the Francis Crick Institute, said, “Our research is focused on exploring how cells repair damage to their DNA, and how failures in this process lead to disease. We are excited to leverage the INDUCE-seq platform’s unique capabilities in directly measuring and quantifying DNA double-strand breaks, and applying this to deepen our understanding of diseases that have genomic instability as a contributing factor, such as ALS.”
Dr. Felix Dobbs, CEO, Broken String Biosciences, commented, “This collaboration with the Crick Institute is validation of our differentiated approach to DNA break-mapping; enabling our team to support world-leading research with insights provided through our INDUCE-seq platform. It demonstrates a fantastic opportunity to apply our expertise across other key research areas to support the advancement of human health.” He added, “There is an unmet clinical need for effective ALS treatments, as well as strategies for earlier diagnosis that can significantly improve patient outcomes.”